Results 1 to 10 of about 3,855 (156)

Eptifibatide bolus dose postductal stenting intervention: A single-center experience [PDF]

Annals of Pediatric Cardiology
Objectives: Stent thrombosis, a potential complication of ductal stenting, is associated with high mortality. This is a catastrophic complication, which can occur acutely (within 24 h), subacutely (within 30 days), or late (≥30 days) after stent ...
Rishika Mehta, Amitabha Chattopadhyay, Aritra Mukherji, Sanjiban Ghosh, Jayita Nandy Das, Pushpanjali Gupta   +5 more
doaj   +3 more sources

Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia [PDF]

Case Reports in Cardiology, 2020
Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case.
Amer Aljundi, Alaa Rahhal, Wafer Dabdoob
doaj   +2 more sources

There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis

Interdisciplinary Neurosurgery, 2021
Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy.
Hari Movva, Rani Rabah, Wondwossen Tekle, Alexandros Georgiadis, Laurie Preston, Hari Kotta, Ameer E. Hassan   +6 more
doaj   +3 more sources

Administration of eptifibatide as rescue therapy during mechanical thrombectomy in acute ischemic stroke [PDF]

Frontiers in Neurology
BackgroundThe success of the technical implementation of mechanical thrombectomy (MT) depends on many factors. Considering the experience of the interventional radiologist and the anatomical vascular differences of individual patients, it has technical ...
David Cernik, David Cernik, Jiri Neumann, Jarmila Neradova, Veronika Hlinena, Pavol Viglas, Pavol Viglas, David Cihlar, Filip Cihlar   +8 more
doaj   +2 more sources

Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]

Xin yixue, 2022
Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease （ICVD）.
Mei Ni, Tian Liang
doaj   +2 more sources

Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]

BMC Cardiovascular Disorders
Background We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi, Zicheng Ling, Shaohua Gu, Tingbo Jiang, Lin Ling   +4 more
doaj   +2 more sources

Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data [PDF]

Frontiers in Medicine
BackgroundAcute respiratory distress syndrome (ARDS) is a clinical syndrome with an extremely high mortality rate, and antiplatelet therapy is an important treatment approach.
Peng Zhang, Wenjing Wang, Ting Zhao, Guoping Wang, Fanyong Shang, Feng Ji   +5 more
doaj   +2 more sources

A woman with eptifibatide (integrilin)‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review [PDF]

Clinical Case Reports
Eptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition.
Morteza Safi, Roozbeh Nazari, Nahid Senobari, Homa Taheri, Pouya Ebrahimi   +4 more
doaj   +2 more sources

Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital

Journal of Research in Pharmacy Practice
Objective: This cross-sectional descriptive study was conducted over 3 months (April–June 2025) among acute coronary syndrome (ACS) patients who received eptifibatide at Shahid Chamran Hospital, Isfahan.
Javad Amini, Mehrnoush Dianatkhah, Mahnaz Momenzadeh, Saeide Bahrani, Ehsan Shirvani, Niloufar Sadat Mirasi, Ali Heidarnezhad   +6 more
doaj   +2 more sources

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont, Héloïse Lebas, Sabrina Mavouna, Eloïse Pascal, Astride Perrot, Adrien Cogo, Marie‐Charlotte Bourrienne, Carine Farkh, Mialitiana Solo Nomenjanahary, Véronique Ollivier, Fatima Zemali, Bernhard Nieswandt, Stéphane Loyau, Martine Jandrot‐Perrus, Eric Camerer, Jean‐Philippe Desilles, Mikael Mazighi, Yacine Boulaftali, Benoît Ho‐Tin‐Noé   +18 more
doaj   +2 more sources